Inclusion myopathy

Inclusion myopathy, also referred to as inclusion body myopathy, encompasses a group of rare genetic muscle disorders characterized by the presence of abnormal protein inclusions within muscle fibers. These inclusions, which can be detected on muscle biopsy, typically contain rimmed vacuoles and filamentous aggregates. The disease primarily affects skeletal muscles, leading to progressive muscle weakness and wasting. Several subtypes of hereditary inclusion body myopathy exist, with varying patterns of muscle involvement. One of the most well-characterized forms is GNE myopathy (inclusion body myopathy type 2), caused by mutations in the GNE gene, which typically presents in young adulthood with distal leg weakness, particularly affecting the tibialis anterior muscle, while characteristically sparing the quadriceps muscles until late in the disease course. Clinical features of inclusion myopathy generally include progressive proximal and/or distal muscle weakness, difficulty walking, foot drop, and eventual loss of ambulation. The pattern of muscle involvement varies depending on the specific genetic subtype. Serum creatine kinase levels may be normal or mildly to moderately elevated. Electromyography typically shows myopathic changes, and muscle biopsy reveals the hallmark rimmed vacuoles and tubulofilamentous inclusions. The disease can significantly impact quality of life as weakness progresses over years to decades. Currently, there is no curative treatment for inclusion myopathy. Management is primarily supportive and includes physical therapy, occupational therapy, orthotic devices, and assistive mobility aids. Research into potential therapies, including substrate replacement approaches such as sialic acid supplementation for GNE myopathy, has been explored in clinical trials, though no disease-modifying therapy has yet received widespread approval. Multidisciplinary care involving neurologists, physiatrists, and genetic counselors is recommended for optimal patient management.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Inclusion myopathy